Long-acting HIV injections show no viral rebound in suppressed teens at 96 weeks
- In a phase 1/2 trial of 144 virologically suppressed adolescents, long-acting cabotegravir plus rilpivirine injections resulted in zero confirmed virological failures through week 96.
- Between July 26, 2021, and August 27, 2022, 144 participants enrolled in the trial, with a median age of 15 years.
- Through week 96, there were no confirmed virological failures among the participants.
- Median week 96 observed trough concentrations of cabotegravir were 2.96 μg/mL and rilpivirine were 89.5 ng/mL, approximating levels seen in adults.
The publication
In a phase 1/2 trial of 144 virologically suppressed adolescents, long-acting cabotegravir plus rilpivirine injections resulted in zero confirmed virological failures through week 96. The study also reported that 24% of participants experienced grade 3 or higher adverse events, with no grade 3 or higher drug-related adverse events occurring after week 96.
Who the findings apply to
The trial enrolled adolescents aged 12 to 17 years who weighed at least 35 kg and were living with HIV-1.
Participants were required to be virologically suppressed at the time of enrollment.
The study was conducted across 18 sites in Botswana, South Africa, Thailand, Uganda, and the USA.
Why this matters
The findings demonstrate that the adult dosing regimen of long-acting cabotegravir plus rilpivirine maintains viral suppression and acceptable safety in adolescents aged 12 to 17 years. This supports the ongoing clinical use of injectable therapy in this age group and informs global approvals for long-acting HIV treatment options.
What the study found
Between July 26, 2021, and August 27, 2022, 144 participants enrolled in the trial, with a median age of 15 years.
Through week 96, there were no confirmed virological failures among the participants.
Median week 96 observed trough concentrations of cabotegravir were 2.96 μg/mL and rilpivirine were 89.5 ng/mL, approximating levels seen in adults.
At least 97% of participants on treatment preferred injectable treatment to daily oral treatment through week 96.
What the result does not establish
The study was a single-arm, non-comparative trial, meaning results were not compared against a control group.
Through week 96, 35 of 144 participants (24%) had an adverse event of grade 3 or higher, with a 95% CI of 17.6 to 32.2.
Three participants had a drug-related adverse event of grade 3 or higher, representing 2% of the cohort with a 95% CI of 0.4 to 6.0.
The trial was not designed to compare efficacy against other antiretroviral regimens, only to evaluate safety and activity of the specific injectable combination.
Authors’ conclusion
“96-week study data show sustained safety and antiviral activity, favourable pharmacokinetics, and good acceptability and tolerability in adolescents living with HIV who were virologically suppressed, inform the growing global approvals, and support the ongoing clinical use of injectable cabotegravir plus rilpivirine in this age group.”
Trial registration
| Registered title | More Options for Children and Adolescents (MOCHA): Oral and Long-Acting Injectable Cabotegravir and Rilpivirine in HIV-Infected Children and Adolescents (MOCHA) |
|---|---|
| Registry status | Phase 1 / Phase 2, interventional, completed |
| Lead sponsor | National Institute of Allergy and Infectious Diseases (NIAID) |
| Registered size | 168 participants — actual enrolment |
| Where | 19 sites in 5 countries (Botswana, South Africa, Thailand, Uganda, United States) |
| Registered primary outcomes |
|
| Results on the registry | Posted May 2024 |
- Start: Apr 2019
- Primary completion: Feb 2023
- Results posted: May 2024
- Completion: Apr 2025
- Paper published: Oct 2026
ClinicalTrials.gov record as held by ENCLAI, last updated Jan 2026. The registry status may have changed since; the link shows the current record.
Study and sources
Safety, antiviral activity, and pharmacokinetics of long-acting cabotegravir plus long-acting rilpivirine in virologically suppressed adolescents living with HIV-1 (IMPAACT 2017/MOCHA): week 96 and end-of-study results from a multinational, phase 1/2, single-arm trial
Early-phase / non-randomised trial · Phase 1/2 · Lancet Child & adolescent health · 2026-10-06
Sources and limitations
- PubMed record PMID 42838065 (PubMed / NLM · 2026-10-07)
- Trial registry NCT03497676 (ClinicalTrials.gov · 2026-10-07)
Related briefings
Follow ENCLAI News
Get new briefings in your news reader. No ENCLAI account needed.
The daily disease brief
One email a day: what changed in official disease reporting worldwide, with the source named for every number. Reported facts only — no forecasts and no interpretation.


